0 results for 'Indefiniteness'
Federal Circuit Tightens Standard for AIA Review
The judges determined that too many patents have been pulled into covered business method review.Delay Bars Addition to IP Suit Against Teva Over Nasal Spray
A Delaware federal judge on Monday blocked plaintiffs in a patent infringement suit against drugmaker Teva Pharmaceuticals USA from amending their complaint to reflect corrections made to a patent for a nasal spray.Delay Bars Addition to IP Suit Against Teva Over Nasal Spray
A Delaware federal judge on Monday blocked plaintiffs in a patent infringement suit against drugmaker Teva Pharmaceuticals USA from amending their complaint to reflect corrections made to a patent for a nasal spray.State Farm Fire & Cas. Co. v. Gates
Click Here for FC&S Legal Expert Analysis State Farm Fire & Cas. Co.v.Gates2016 WL 3570793Only the Westlaw citation is currently available.United…The Importance of Patent Monitoring in a Post-AIA World
Companies should implement programs that include monitoring the patent filings and patent activity of their current and potential competitors.Using Post-Grant Review as Part of an Integrated IP Protection Strategy
The America Invents Act created new tools for challenging patents in the U.S. Patent and Trademark Office. These are inter partes review, covered business method patent review and post-grant review.The Interplay Between Indefiniteness and Inter Partes Review
Inter partes review (IPR) is an extremely effective alternative or supplement to litigation, and there are appreciable benefits to challenging an issued patent in an IPR rather than before a federal district court. In an IPR, unlike a patent lawsuit, a challenged patent is not presumed to be valid, nor is clear and convincing evidence required to demonstrate invalidity. Rather, the challenger (petitioner) need only ­demonstrate invalidity by a ­preponderance of the evidence.Merck Wins Patent Battle Over Hepatitis C Drugs
As the case moves on to a damages phase, lawyers for Merck & Co. Inc. will push for a 10 percent cut of sales on Gilead Sciences Inc.'s blockbuster drug sofosbuvir.Federal Circuit Answers Question Looming Over PTAB Process
Petitions for inter partes review don't have to be accepted on an all-or-nothing basis, Judge Timoty Dyk ruled in a dispute between Synopsys and Mentor Graphics.Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now
Practical Guidance Journal: Protecting Work Product in a Generative AI World
Brought to you by LexisNexis®
Download Now